Ubs Oconnor LLC Viridian Therapeutics, Inc.\De Transaction History

Ubs Oconnor LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.26 $74,240 - $110,464	-6,400 Reduced 38.89%	10,057 $130,000
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $231,449 - $322,594	-13,543 Reduced 45.14%	16,457 $288,000
Q4 2023 Feb 14, 2024	SELL	$11.12 - $22.5 $609,776 - $1.23 Million	-54,836 Reduced 64.64%	30,000 $653,000
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $151,600 - $247,000	10,000 Added 13.36%	84,836 $1.3 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $1.69 Million - $2.22 Million	74,836 New	74,836 $1.78 Billion
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $73,041 - $109,679	-2,917 Reduced 4.39%	63,543 $1.62 Million
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $289,399 - $458,293	-15,410 Reduced 18.82%	66,460 $0
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $508,046 - $1.21 Million	47,481 Added 138.07%	81,870 $1.68 Billion
Q2 2022 Aug 12, 2022	BUY	$9.55 - $19.0 $137,414 - $273,391	14,389 Added 71.95%	34,389 $397,000
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $335,800 - $417,600	20,000 New	20,000 $369,000

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $789M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.